Newland Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022	Dec '20 Dec 31, 2020
Cash & Equivalents	444.66	281.58	270.02	51.13	34.21	36.45
Trading Asset Securities	271.14	525.16	589.5	701.36	8.67	-
Cash & Short-Term Investments	715.8	806.75	859.52	752.49	42.88	36.45
Cash Growth	-10.95%	-6.14%	14.22%	1654.94%	17.63%	-34.12%
Accounts Receivable	225.27	332.61	240.9	360.46	269.6	179.29
Other Receivables	0.18	0.24	0.19	0.26	0.16	0.3
Receivables	225.45	332.85	241.09	360.72	269.76	179.6
Inventory	82.28	45.06	31	53.52	78.57	49.42
Prepaid Expenses	-	-	-	-	-	1.25
Other Current Assets	11.57	10.37	25.04	20.38	9.8	1.78
Total Current Assets	1,035	1,195	1,157	1,187	401	268.49
Property, Plant & Equipment	650.35	574.78	388.2	295.52	225.67	210.5
Other Intangible Assets	49.88	36.82	38.08	38.77	39.71	39.9
Long-Term Deferred Tax Assets	-	-	-	-	1.01	0.83
Long-Term Deferred Charges	1.76	3.38	5.61	1.29	-	-
Other Long-Term Assets	7.64	3.73	20.96	11.08	0.51	2.23
Total Assets	1,745	1,814	1,610	1,534	667.9	521.96
Accounts Payable	102.08	138.66	87.75	106.37	80.26	43.5
Accrued Expenses	14.69	23.78	30.33	18.18	27.81	23.56
Short-Term Debt	-	0.73	-	-	91.33	90.12
Current Portion of Long-Term Debt	-	-	-	-	4.66	-
Current Portion of Leases	2.78	-	1.99	2.84	-	-
Current Income Taxes Payable	1.4	-	-	-	3.05	4.26
Current Unearned Revenue	1.68	5.32	4.43	4.61	1.68	0.41
Other Current Liabilities	41.77	48.3	14.96	24.01	11.8	15.89
Total Current Liabilities	164.41	216.78	139.47	156.01	220.58	177.73
Long-Term Debt	-	-	-	-	30.39	20.02
Long-Term Leases	3.3	2.25	0.73	2.88	-	-
Long-Term Unearned Revenue	41.69	41.88	10.04	10.3	10.56	10.81
Long-Term Deferred Tax Liabilities	12.86	9.77	9.78	5.39	-	-
Total Liabilities	222.26	270.69	160.02	174.58	261.53	208.57
Common Stock	392.08	280.06	200.04	133.36	100	100
Additional Paid-In Capital	532.74	644.77	724.78	791.46	5.49	1.78
Retained Earnings	590.58	610.7	517.09	424.79	292.48	207.5
Comprehensive Income & Other	6.84	6.67	6.11	6.33	4.56	4.11
Total Common Equity	1,522	1,542	1,448	1,356	402.53	313.39
Minority Interest	0.22	0.85	1.47	3.25	3.85	-
Shareholders' Equity	1,522	1,543	1,449	1,359	406.38	313.39
Total Liabilities & Equity	1,745	1,814	1,610	1,534	667.9	521.96
Total Debt	6.09	2.98	2.72	5.72	126.38	110.14
Net Cash (Debt)	709.71	803.77	856.8	746.77	-83.5	-73.69
Net Cash Growth	-11.59%	-6.19%	14.73%	-	-	-
Net Cash Per Share	1.81	2.05	2.19	2.48	-0.28	-0.25
Filing Date Shares Outstanding	392.08	392.08	392.08	392.08	294	294
Total Common Shares Outstanding	392.08	392.08	392.08	392.08	294	294
Working Capital	870.69	978.24	1,017	1,031	180.43	90.76
Book Value Per Share	3.88	3.93	3.69	3.46	1.37	1.07
Tangible Book Value	1,472	1,505	1,410	1,317	362.82	273.49
Tangible Book Value Per Share	3.76	3.84	3.60	3.36	1.23	0.93
Buildings	-	211.94	169.21	151.69	148.36	128.24
Machinery	-	295.69	235.66	187.31	125.82	115.55
Construction In Progress	-	222.1	106.7	55.35	33.02	32.52

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.